Relay Therapeutics (RLAY) Retained Earnings (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Retained Earnings data on file, last reported at -$2.1 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 5526415.79% year-over-year to -$2.1 billion in Q1 2026; TTM through Mar 2026 was -$2.1 billion, a 5526415.79% decrease from a year earlier, with the FY2025 full-year figure at $2.6 billion, up 248.48% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.1 billion, down from $2.6 billion in the prior quarter.
• Over the last five years, Retained Earnings for RLAY reached as high as $2.6 billion in Q4 2025 and fell as low as -$2.1 billion in Q1 2026.
• Historically, Retained Earnings has averaged $124.1 million across 5 years, with a median of -$9.2 million in 2022.
• Across the five-year window, Retained Earnings surged 185681.43% in 2022 and plunged 5526415.79% in 2026, its largest moves.
• Year by year, Retained Earnings stood at $2.0 billion in 2022, then plunged by 100.01% to -$196000.0 in 2023, then plunged by 886782.65% to -$1.7 billion in 2024, then jumped by 248.48% to $2.6 billion in 2025, then sank by 181.37% to -$2.1 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$2.1 billion in Q1 2026, $2.6 billion in Q4 2025, and -$2.0 billion in Q3 2025.